BERLIN, Oct. 15, 2024 /PRNewswire/ -- Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to ...

Both meetings included interactive case studies led by the international and regional faculties, mimicking real world clinical scenarios for attending doctors. Derek O’Leary, Regional Managing ...

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years. An important investment in the future is the new ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

"We continue to pursue claims against Boehringer Ingelheim for its wrongdoing in exposing millions of people to a known carcinogen for over a decade. Our fight against Boehringer Ingelheim ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

The first was for Boehringer Ingelheim and GlaxoSmithKline, another Zantac manufacturer, and the second was for GlaxoSmithKline alone. Next up: California's first Zantac trial is set to begin jury ...